Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
6-month open-label biomarker study of Gilenya in relapsing-remitting multiple sclerosis
2010-022066-28Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fingolimod in multiple sclerosis (MS), sponsored by Novartis. Primary endpoint: Change in naive and memory T-cell subsets at month 6 versus baseline. Started Sep 2010; status: completed.
02
Drugs
fingolimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2010-022066-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022066-28.